MannKind Reports 30-week Results From Phase 4 INHALE-3 Study - Quick Facts
Express News | MannKind Corp: Look Forward to Discussing More Details of 30-Week Study Results at Conferences in 2025
Express News | MannKind Corp: Announced Top-Level 30-Week Results From Its Phase 4 Inhale-3 Study
MannKind's Afrezza Demonstrates A1c Control In Diabetes Patients During MannKind's Phase 4 Trial
More Adults With Type 1 Diabetes Achieved A1C Goal (
10 Health Care Stocks With Whale Alerts In Today's Session
MannKind Corporation (MNKD): Short Seller Sentiment Is Bearish
Exchange-Traded Funds, Equity Futures Slightly Higher Pre-Bell as Investors Weigh Fed Rate Cut
Express News | MannKind Announces Clearance From Pmda to Initiate Phase 3 Clinical Trial (ICON-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (Ntm) Lung Disease
Improved Revenues Required Before MannKind Corporation (NASDAQ:MNKD) Stock's 27% Jump Looks Justified
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
Leerink Partners Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $8
Leerink Partners analyst Faisal Khurshid initiates coverage on $MannKind(MNKD.US)$ with a buy rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 90.0
MannKind Coverage Assumed by Leerink Partners at Outperform
MannKind Price Target Announced at $8.00/Share by Leerink Partners
Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 80,000 Shares of MannKind ...
MannKind Up Nearly 11%, On Track for Largest Percent Increase Since August 2023 -- Data Talk
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
MannKind Analyst Ratings
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Raises Target Price to $12
Oppenheimer analyst Andreas Argyrides maintains $MannKind(MNKD.US)$ with a buy rating, and adjusts the target price from $10 to $12.According to TipRanks data, the analyst has a success rate of 49.0%
Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)